Quarterly Result14 May 2025, 01:16 pm
Sai Life Sciences Reports 105% Increase in Net Profit for FY25
AI Summary
Sai Life Sciences Limited, a Contract Research, Development and Manufacturing Organization (CRDMO), has announced its financial results for the quarter and year ended March 31, 2025. The company reported a 16% year-on-year growth in revenue from operations, a 42% increase in EBITDA, and a significant 105% increase in net profit for FY25. The Q4FY25 highlights include a 32% increase in revenue from operations and a 57% increase in net profit compared to Q4FY24.
Key Highlights
- Revenue from Operations for FY25 was ₹ 16,950 Cr, a 16% increase from ₹ 1,465 Cr in FY24
- EBITDA for FY25 stood at ₹ 425 Cr, a 42% increase from ₹ 300 Cr in FY24
- PAT for FY25 was ₹ 170 Cr, a 105% increase from ₹ 83 Cr in FY24
- Q4FY25 Revenue from Operations was ₹ 580 Cr, a 32% increase from ₹ 439 Cr in Q4FY24
- Q4FY25 EBITDA was ₹ 161 Cr, a 30% increase from ₹ 124 Cr in Q4FY24
- Q4FY25 PAT was ₹ 88 Cr, a 57% increase from ₹ 56 Cr in Q4FY24